Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

TheMotleyFool

0 0

1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On: https://g.foolcdn.com/editorial/images/773981/gettyimages-170619155.jpg

One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound have become staples for treating diabetes and obesity.

Eli Lilly (NYSE: LLY) is the developer of Mounjaro and Zepbound, two popular medications used to treat those conditions. The main compound in each drug is called tirzepatide, and Lilly has been actively exploring additional use cases for the breakthrough medicine.

Let's break down the GLP-1 market, and analyze why investors may not want to sleep on Lilly's future.

Source Fool.com

Like: 0

LLY

Share